Misonix Showcases BoneScalpel™ And SonaStar® For A Worldwide Audience At The 82nd American Neurological Surgeons Annual Scientific Meeting
FARMINGDALE, N.Y., April 15, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently exhibited and highlighted the BoneScalpel and SonaStar Ultrasonic Surgical Aspiration System at the 82nd American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Francisco, CA from April 5-9, 2014.
The Misonix BoneScalpel is a novel, ultrasonic surgical device that enables rapid, safe and precise osteotomies. It is designed to achieve clean cuts through osseous structures with minimal loss of viable bone, substantially reduced intra-operative bleeding, thereby keeping the surgical site clear of blood. Reductions in O.R. time can also be significant. SonaStar offers precise soft tissue aspiration and effective removal of osseous structures. SonaStar's state-of-the-art wireless technology includes the most powerful handpiece on the market today. More than 3,000 distinguished neurosurgeons and health care professionals from around the world attended the AANS Annual Meeting and its exhibits. Key neurosurgeon subspecialties were focused in the areas of spine, tumor and cerebrovascular.
Eric Woodard, MD, Chief of Neurosurgery at Boston's New England Baptist Hospital describes his experience as a long-term BoneScalpel user: "We have used the BoneScalpel in well over 1,000 cases now and are seeing numerous advantages. We now use it essentially on every spine patient, and we have found in our practice that it significantly reduces operative time, decreases blood loss, and markedly increases the amount of residual local bone available for grafting. In so doing, it significantly reduces overall operating room time and cost. As a surgeon, I value the safety, convenience and speed the device adds to my bone work. It has extended my surgical career by five years."
Anil Nanda, MD, Professor and Chairman of the Department of Neurosurgery at LSU Health Sciences Center at Shreveport, LA, recently trialed the SonaStar. Dr. Nanda commented, "I recently used the SonaStar ultrasonic aspirator during a difficult case. I was very thankful for the SonaStar as it performed flawlessly to precisely target and remove the tumor while sparing critical vessels. This advancement in medical technology likely shaved at least two hours off my surgical procedure."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, "The AANS represents one of the foremost neurosurgical meetings attracting the best neurosurgeons from all points of the globe. I was pleased to see the level of interest continuing to accelerate in the neurosurgery community for BoneScalpel and SonaStar. Many of the AANS attendees who stopped by the Misonix booth expressed their eagerness to trial SonaStar and BoneScalpel at their hospitals soon after the meeting concluded. I was very pleased to meet with so many enthusiastic new users of the BoneScalpel and the SonaStar from around the world."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.